Gilead Sciences
Murali Subramanian is a Principal Scientist (Director) in DMPK at Gilead Sciences since June 2022, previously holding a similar position at Janssen Inc. from May 2018 to July 2022, where Murali led DMPK programs across various therapeutic areas. Prior experience includes leadership roles in biotransformation and drug metabolism at Biocon Bristol-Myers Squibb Research Centre (Syngene International) from 2010 to 2018, as well as postdoctoral research at the University of Minnesota and Iowa State University. Murali holds a PhD in Chemical Engineering/Biotechnology from Iowa State University and a BE in Chemical Engineering from the National Institute of Technology Karnataka.
This person is not in any teams